Status:
TERMINATED
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Lead Sponsor:
Papageorgiou General Hospital
Conditions:
Secondary Hyperparathyroidism
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day. The 2nd phase ...
Eligibility Criteria
Inclusion
- Age older than 18 yrs
- On hemodialysis for at least 3 months (thrice weekly)
- iPTH \>300pg/ml or histological evidence of secondary hyperparathyroidism
- Calcium \> 8.1 mg/dl
Exclusion
- Unstable clinical condition
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00446329
Start Date
July 1 2006
Last Update
October 29 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Papageorgiou General Hospital
Thessaloniki, Greece, 56403